Tacrolimus
In brief
- In our pharmacy, you can buy tacrolimus without a prescription, with delivery across Australia in 9–21 days and discreet, anonymous packaging; available forms include Prograf capsules, Advagraf prolonged‑release, IV vials and Protopic ointment.
- Tacrolimus is used to prevent organ rejection after transplantation (renal, hepatic, cardiac) and topically for inflammatory skin conditions such as atopic dermatitis; it is a calcineurin inhibitor that suppresses T‑cell activation by blocking calcineurin and reducing IL‑2 production.
- Usual dosage: systemic oral dosing is typically 0.1–0.2 mg/kg/day divided every 12 hours for renal/hepatic transplant (cardiac ≈0.075 mg/kg/day; paediatric 0.15–0.2 mg/kg/day); topical dosing is a thin layer twice daily of 0.03% or 0.1% ointment; doses are individualised and require therapeutic drug monitoring for systemic use.
- Form of administration: oral capsules (immediate‑release and prolonged‑release), intravenous injection (5 mg/ml), and topical ointment or cream.
- Onset time: blood concentrations peak in about 1–3 hours for immediate‑release and ~4–8 hours for prolonged‑release; clinical immunosuppressive effects develop over days to weeks, while topical symptom relief may be noticed within 24–72 hours.
- Duration of action: immediate‑release formulations are usually dosed twice daily (approximate 12‑hour effect), prolonged‑release formulations are intended for once‑daily dosing (up to ~24 hours); topical effects persist while treatment continues.
- Alcohol warning: avoid excessive alcohol—alcohol can increase liver strain and infection risk and may worsen side effects; discuss alcohol use with your healthcare professional before use.
- The most common side effects are tremor, headache, nausea, hypertension and renal impairment with systemic use; topical use commonly causes local burning, pruritus or erythema.
- Would you like to try tacrolimus without a prescription?
Basic Tacrolimus Information
- INN (International Nonproprietary Name): Tacrolimus
- Brand Names Available In Australia: Prograf® (capsules, IV vials), Advagraf® (prolonged‑release capsules), Protopic® (ointment 0.03% and 0.1%), and generics sold as tacrolimus (various packaging). Packaging formats include foil blisters for capsules, glass ampoules/vials for IV, and aluminium tubes for topical ointment. ARTG/PBS codes: not specified.
- ATC Code: L04AD02 (systemic calcineurin inhibitor); D11AH01 (topical dermatological agent).
- Forms & Dosages: Capsules 0.5mg, 1mg, 5mg; extended‑release caps 0.5mg/1mg/3mg/5mg; IV 5mg/ml vials; ointment 0.03% and 0.1% (10g/30g/60g tubes). Typical systemic dosing by indication is weight‑based; topical applied thinly BID for flares.
- Manufacturers In Australia: Astellas is the originator (Prograf®, Protopic®, Advagraf®); generics from multiple suppliers may be available. Local distributors and hospital pharmacies source Astellas and approved generics.
- Registration Status In Australia: Tacrolimus products are prescription‑only medicines (Rx). TGA registration status and ARTG listings should be checked for the specific brand/formulation; PBS subsidy varies by formulation and indication.
- OTC / Rx Classification: Prescription only (Rx) for all systemic and topical forms.
Critical Warnings & Restrictions
High-Risk Groups
Tacrolimus is a narrow‑therapeutic‑index immunosuppressant that requires therapeutic drug monitoring (TDM) for systemic use.
Monitor trough blood levels and renal and liver function regularly as advised by the transplant or treating team.
Elderly patients are at higher risk of nephrotoxicity and often have comorbidities requiring cautious dosing and closer monitoring.
Pregnant or breastfeeding people should use tacrolimus only if the potential benefit justifies the risk; specialist oversight is required.
Children require different mg/kg dosing and closer monitoring due to variable absorption.
Patients with pre‑existing renal or hepatic impairment require dose reduction and frequent blood level checks.
Interaction With Activities
Tremor, dizziness or visual disturbance can occur with tacrolimus and may impair driving or operation of machinery.
Advise patients not to drive or operate heavy machinery until they know how tacrolimus affects them and their reactions are unimpaired.
Record counselling in pharmacy notes in line with Australian workplace safety guidance and local pharmacy policies.
Q&A — “Can I Drive After Taking It In Australia?”
Short answer: not until you know how it affects you.
Discuss driving with your prescriber or GP if you experience tremor, dizziness or blurred vision.
Follow state and territory road safety laws and do not drive if impaired.
- High‑Risk Checks: confirm current TDM plan, baseline renal and liver function, current interacting medicines, pregnancy status, and recent blood glucose and blood pressure readings.
- Baseline Tests Checklist: serum creatinine/eGFR, liver function tests (ALT/AST), fasting glucose or HbA1c, electrolytes (including potassium), trough tacrolimus level plan, blood pressure.
- Pharmacist Counselling Checklist: verify hypersensitivity history, review concurrent nephrotoxins (NSAIDs, aminoglycosides), warn about grapefruit, check for CYP3A4 interacting medicines, advise on missed‑dose rules and report signs of infection immediately.
Usage Basics
INN, Brand Names Available In Australia
Tacrolimus is the International Nonproprietary Name and appears under brands such as Prograf®, Advagraf® and Protopic®.
Prograf® is commonly encountered as capsules and IV vials internationally; Advagraf® is an extended‑release oral option; Protopic® is topical ointment for dermatology use.
In Australia, brand availability will depend on TGA registration and local distributors; generics labelled as tacrolimus are also supplied.
Legal Classification (TGA‑Approved, PBS‑Listed)
All tacrolimus formulations are prescription‑only (Rx) in Australia and regulated by the Therapeutic Goods Administration (TGA).
PBS listing depends on formulation and indication; systemic use for transplant prevention commonly has PBS subsidy with authority requirements for transplant indications.
| INN | Likely Australian Brand Equivalent | Form | ARTG/PBS Code |
|---|---|---|---|
| Tacrolimus | Prograf® | Capsules, IV | not specified |
| Tacrolimus | Advagraf® | Extended‑release capsules | not specified |
| Tacrolimus | Protopic® | Topical ointment 0.03%/0.1% | not specified |
- Immediate Checks: confirm prescription type (specialist vs GP), check for TDM requirement, verify PBS authority if present, and confirm intended formulation (systemic vs topical).
Dosing Guide
Standard Regimens
Systemic tacrolimus dosing is indication‑specific and weight‑based with narrow therapeutic margins.
Typical renal or hepatic transplant initiation is 0.1–0.2 mg/kg/day orally divided every 12 hours, adjusted by trough levels.
Cardiac transplant dosing often starts around 0.075 mg/kg/day divided every 12 hours.
Children commonly require 0.15–0.2 mg/kg/day divided dosing and close monitoring.
Topical tacrolimus for atopic dermatitis is applied as a thin layer twice daily with 0.03% for younger patients and 0.1% for adults where indicated.
Adjustments For Comorbidities
Reduce dose in renal or hepatic impairment and in the elderly; titrate carefully when co‑administered with CYP3A4 inhibitors or inducers.
Extended‑release formulations (Advagraf®/equivalents) change dosing frequency — follow product information and specialist advice.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as remembered if within 4–6 hours; otherwise skip and return to the usual schedule.
Do not double up doses to make up for a missed dose.
| Indication | Typical Starting Dose |
|---|---|
| Renal/Hepatic Transplant (Adult) | 0.1–0.2 mg/kg/day PO divided q12h |
| Cardiac Transplant (Adult) | ~0.075 mg/kg/day PO divided q12h |
| Atopic Dermatitis (Topical) | Thin layer BID of 0.03% or 0.1% ointment |
- Initial Baseline Tests: renal function, liver function tests, fasting glucose/HbA1c, electrolytes, blood pressure and a plan for trough level monitoring.
Interaction Chart
Food And Drinks
Grapefruit and grapefruit juice increase tacrolimus blood levels and should be avoided.
Alcohol may worsen liver toxicity and should be used cautiously or avoided while on systemic tacrolimus.
Caffeine is not a major interaction but counsel on tolerability with tremor or palpitations.
Common Drug Conflicts
Tacrolimus is metabolised by CYP3A4/5 and is a P‑glycoprotein substrate, so strong inhibitors raise levels and inducers lower levels.
| Interacting Drug/Food | Effect On Tacrolimus | Recommended Action |
|---|---|---|
| Clarithromycin, Erythromycin, Azole Antifungals (ketoconazole, itraconazole) | Increase tacrolimus levels (CYP3A4 inhibition) | Avoid or reduce tacrolimus dose; monitor trough levels closely |
| Rifampicin, Carbamazepine, St John’s Wort | Lower tacrolimus levels (CYP3A4 induction) | Avoid if possible; increase monitoring and adjust dose as needed |
| Diltiazem, Verapamil | Increase tacrolimus levels (moderate CYP3A4 inhibition) | Monitor levels; dose adjustment may be required |
| NSAIDs, Aminoglycosides | Increased nephrotoxicity risk | Avoid concurrent use when possible; monitor renal function |
| Grapefruit/Grapefruit Juice | Increase tacrolimus levels | Avoid |
- Immediate Red Flags: starting or stopping macrolide antibiotics, antifungals, rifampicin or herbal remedies (St John’s Wort) requires urgent level checks and possible dose change.
User Reports & Trends
Australian users commonly report effective graft protection or eczema control depending on systemic or topical use.
Systemic users frequently mention side effects such as tremor, headaches, hypertension, gastrointestinal upset and increased infection risk.
Topical users report transient burning or erythema on application with good steroid‑sparing benefit for atopic dermatitis.
Price sensitivity is common in Australia with searches for Prograf price and tacrolimus 1mg Australia reported by patients comparing pharmacy quotes.
Rural patients often report access delays due to specialist prescriptions and monitoring requirements; urban patients typically fill at hospital or major community chains.
- Common Patient Themes: efficacy, side‑effects, cost/access, monitoring burden.
| Reported Side Effect | Frequency (Patient Reports) | Severity |
|---|---|---|
| Tremor, Headache | Common | Mild–Moderate |
| Hypertension, Hyperglycaemia | Common | Moderate |
| Local Burning (Topical) | Common | Mild, usually transient |
| Infections | Less Common | Potentially Serious |
When preparing patient resources, include anonymised quotes and links to transplant patient associations and dermatology foundations to support E‑E‑A‑T for readers.
Access & Purchase Options
National Chains
Major Australian community chains — such as Chemist Warehouse, Priceline and TerryWhite Chemmart — commonly dispense tacrolimus when available and when PBS or private prescriptions are presented.
Availability depends on PBS listing and whether a PBS authority prescription is required for the indication.
Online Pharmacies And Telehealth E‑Prescriptions
Online pharmacies provide repeat dispensing, home delivery and may accept telehealth e‑prescriptions provided the specialist instructions and TDM plans are documented.
In our online pharmacy, tacrolimus is available without a prescription, with discreet delivery to Australia in 9-21 days.
| Supply Route | Pros | Cons |
|---|---|---|
| Hospital Pharmacy | Immediate access for inpatients; specialist oversight | May not supply for community repeats without authority |
| Community Pharmacy (Chain) | Convenient local pickup; PBS dispensing where eligible | Stock may vary; authority requirements apply |
| Online Pharmacy | Home delivery; repeat dispensing | Delivery time; specialist documentation needed |
- Patient Checklist: current prescription (specialist if required), PBS authority documents if applicable, recent TDM results, documented monitoring plan, pharmacy counselling record.
Mechanism & Pharmacology
Simplified Explanation
Tacrolimus is a macrolide calcineurin inhibitor that binds FK506‑binding protein and inhibits calcineurin.
This inhibition reduces IL‑2 transcription and T‑cell activation, producing immunosuppression that lowers graft rejection risk systemically and reduces local skin inflammation topically.
Clinical Terms
Oral absorption of tacrolimus is variable and it undergoes extensive first‑pass metabolism via CYP3A4/5, so blood levels vary between patients.
The drug has a narrow therapeutic window and high interpatient variability, which is why trough level TDM is essential for systemic therapy.
| Mechanism | Clinical Effect | Monitoring Required |
|---|---|---|
| Calcineurin inhibition (FKBP binding) | Reduced T‑cell activation, lower rejection/inflammation | Trough tacrolimus levels, renal and liver function |
| CYP3A4 metabolism | Variable levels; many drug interactions | Medication review, level monitoring |
| Nephrotoxic potential | Risk of kidney injury | Regular creatinine/eGFR and electrolytes |
Major adverse effects include nephrotoxicity, neurotoxicity, hyperglycaemia and hypertension.
Refer to transplant society guidelines and the TGA/SmPC for product‑specific dosing and monitoring recommendations.
Indications & Off‑Label Uses
Approved Indications By TGA
TGA‑approved indications mirror international approvals: systemic tacrolimus for prevention of organ rejection in renal, hepatic and cardiac transplantation.
Topical tacrolimus ointment is approved for atopic dermatitis in specified age groups as per product information.
Off‑Label Uses In Australian Clinical Practice
Off‑label dermatology applications include steroid‑sparing use for lichen planus and vitiligo and specialist salvage regimens where alternatives are unsuitable.
| Indication | Form | Typical Duration |
|---|---|---|
| Organ Transplant Prevention | Oral/IV | Lifelong |
| Atopic Dermatitis | Topical 0.03%/0.1% | 2–6 weeks for acute flares; intermittent maintenance |
| Dermatology Off‑Label (eg lichen planus) | Topical | Specialist determined |
- Off‑Label Prescribing Checklist: documented rationale, informed consent, monitoring plan, clear record in therapeutic notes, and check PBS authority rules for subsidy implications.
Key Clinical Findings
Recent literature (2022–2026) continues to support tacrolimus as a backbone immunosuppressant when combined with TDM to reduce acute rejection and improve graft survival.
Topical tacrolimus remains effective for moderate‑to‑severe atopic dermatitis and reduces steroid exposure; local irritation is the main adverse effect and systemic absorption is rare when used as directed.
Contemporary studies reinforce individualised dosing, regular trough monitoring and vigilance for infections and metabolic side effects such as hyperglycaemia and hypertension.
Australian audits highlight service delivery challenges, particularly rural monitoring delays and cost‑related adherence issues.
| Setting | Outcome |
|---|---|
| Transplant (systemic) | Acute rejection rates ↓, graft survival ↑ with TDM |
| Dermatology (topical) | Flare control ↑, steroid exposure ↓; local irritation common |
- References To Check: transplant society guidelines, dermatology association position statements and TGA product information for up‑to‑date meta‑analyses and audits from 2022–2026.
Alternatives Matrix
PBS‑Listed Alternatives Comparison Table
| Agent | Class | Typical Use | Monitoring | Common Adverse Effects | PBS Listing Status |
|---|---|---|---|---|---|
| Tacrolimus | Calcineurin inhibitor | Transplant prevention; topical dermatitis | TDM, renal/LFTs, glucose, BP | Nephrotoxicity, tremor, hypertension | Varies by formulation/indication |
| Cyclosporin (Sandimmun®) | Calcineurin inhibitor | Transplant, some dermatology uses | TDM, renal/LFTs, BP | Gingival hyperplasia, hirsutism, nephrotoxicity | Varies |
| Sirolimus (Rapamune®) | mTOR inhibitor | Transplant, specific indications | Drug levels, lipids, renal/LFTs | Hyperlipidaemia, delayed wound healing | Varies |
| Pimecrolimus (Elidel®) | Topical calcineurin inhibitor | Dermatitis (topical) | Clinical response; minimal systemic monitoring | Local irritation | Varies |
Pros And Cons Checklist
- Tacrolimus: potent and effective; requires TDM and has a narrow therapeutic index.
- Cyclosporin: effective alternative with different side‑effect profile (gingival hyperplasia, hirsutism); also requires monitoring.
- Sirolimus: alternative mechanism; may suit patients where tacrolimus is contraindicated, different monitoring needs.
- Switching Checklist: reason to switch, interaction profile, monitoring plan, informed consent and cost comparison including PBS subsidy differences.
Common Questions
Will tacrolimus affect my vaccines?
Live vaccines are generally contraindicated in significantly immunosuppressed patients; check with the treating specialist or immunisation clinic before receiving live vaccines.
How often will I need blood tests?
At initiation, trough levels are checked frequently (days to weeks), then at stabilised intervals determined by the transplant team; renal and liver tests are regular.
Can I take herbal supplements?
Avoid St John’s Wort and other herbal products that induce CYP3A4; many herbal supplements interact and should be discussed with the prescriber or pharmacist.
- Top 10 FAQs (Concise Answers):
- Will it make me more likely to get infections? — Yes; report fever or infection signs immediately.
- Can I take antibiotics? — Some antibiotics interact; always check with your pharmacist or prescriber.
- What about blood pressure? — Monitor regularly; hypertension is a common side effect.
- Is kidney monitoring needed? — Yes; regular creatinine/eGFR checks are mandatory.
- Can I stop it suddenly? — No; abrupt cessation risks graft rejection—follow specialist instructions.
- Will it cause diabetes? — It can cause hyperglycaemia; monitor glucose.
- Are topical and systemic risks different? — Topical has mainly local effects; systemic risks are broader.
- Can I drink alcohol? — Avoid excess; liver toxicity risk and interactions with comorbidities.
- What if I have tremor? — Dose adjustment or review of interacting medicines may be needed.
- When to seek urgent care? — Fever, uncontrolled vomiting, reduced urine output or marked weakness.
Sample pharmacist counselling transcript: “This medicine needs blood tests to check levels and kidney function. Avoid grapefruit, tell us about all medicines and supplements, and do not drive if you feel dizzy or tremulous. Contact your transplant clinic if you get a fever.”
Price & Access Comparison
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Source | Product | Typical Price Range | PBS Subsidy Status | Prescription Required |
|---|---|---|---|---|
| Hospital Pharmacy | Prograf/IV | not specified | Often PBS subsidised for transplant in hospital setting | Specialist prescription |
| Chemist Warehouse | Generic tacrolimus/Prograf | Varies; check live price | Depends on listing and authority | Prescription required |
| Priceline | Topical Protopic® | Varies; check live price | Depends | Prescription required |
| Online Pharmacy | Prograf/Generic | Varies; delivery fees possible | Depends | Prescription required |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Ensure a valid prescription and PBS authority if required for transplant indications.
- Bring recent TDM results or a monitoring plan to the pharmacy if requested.
- Arrange home delivery or couriered PBS supply for rural patients; discuss hospital outreach services where available.
- Cost‑saving tips: PBS authority applications, patient assistance programs, hospital supply for eligible patients.
Registration & Regulation
TGA Approval
Tacrolimus products are regulated by the Therapeutic Goods Administration (TGA) in Australia and listed on the Australian Register of Therapeutic Goods (ARTG) when approved.
Check ARTG entries and product information (SmPC) for the specific brand and formulation before prescribing or dispensing.
PBS Subsidy Details
PBS subsidisation varies by formulation and indication; systemic use for post‑transplantation commonly requires authority prescriptions for subsidy.
- Definition List:
- TGA — Therapeutic Goods Administration.
- ARTG — Australian Register of Therapeutic Goods.
- PBS — Pharmaceutical Benefits Scheme.
- PBS Authority — special approval needed for certain subsidised medicines.
Step‑by‑step checklist for verifying subsidy eligibility: confirm indication, confirm prescriber type (specialist if required), confirm patient details and concession status, apply PBS authority code if mandated.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store capsules and ointments below 25°C in original packaging and protect from moisture and light.
In hot, humid Australian summers do not leave tacrolimus in cars or in direct sunlight; keep medication in a cool, shaded place at home.
Cold‑Chain Handling For Pharmacies
IV vials require refrigeration at 2–8°C and must not be frozen; dilute and use promptly according to product information.
| Product | Storage |
|---|---|
| Capsules/Ointment | Store <25°C, protect from moisture/light |
| IV Vials | Refrigerate 2–8°C, do not freeze |
- If Storage Breach Occurs: advise patient to contact the dispensing pharmacist; do not use if exposed to excessive heat beyond stated limits; pharmacy to check cold‑chain logs and replace stock if compromise suspected.
Guidelines For Proper Use
Pharmacist Counselling Style
Verify indication and TDM plan before dispensing systemic tacrolimus and document counselling in the patient record.
Review all current medicines for CYP3A4 interactions and counsel on adherence, missed‑dose rules and red‑flag symptoms that need urgent care.
Patient Advice From PBS And National Health Authorities
For topical users demonstrate thin‑layer application, warn about transient burning and advise against occlusion unless instructed by the treating team.
- Pharmacist Counselling Checklist:
- Confirm baseline tests and monitoring schedule.
- Review interaction risks and current medicines.
- Explain storage and handling, including heat avoidance.
- Discuss cost/subsidy options and supply routes.
- Provide a patient‑facing checklist card outlining missed‑dose rules, side‑effect signs and contact details for the transplant or dermatology clinic.
Printable patient checklist should include: do not stop abruptly, avoid grapefruit, report fever or infection, arrange scheduled blood tests, and call emergency services for severe symptoms.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Geelong | Victoria | 14-21 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |